Drugs / ABBV-8736
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07413133 | Feb → Jun 2026 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT07141199 | Sep 2025 → Mar 2026 | — | AbbVie | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06548542 | Sep 2024 → Jan 2030 expected | Crohn disease | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-8736 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06548542 ↗ |
| Route | Intravenous | “ABBV-8736 is given as an infusion into the vein.” NCT06548542 ↗ |